INmune Bio

INMB · Nasdaq · United States

Share price · INMB

$1.03-1.08 (-51.18%) 3M

close as of 2026-11-18 · 24h delayed · vol 771K (2.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INMB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+7.3%
  2. 30 Oct 2026-9.4%
  3. 16 Sep 2026-9.3%
  4. 10 Jul 2026+8.4%

    Nothing announced by INMB that day or the session before.

  5. 29 Jun 2026+14.1%
  6. 18 Jun 2026+11.5%
  7. 14 May 2026+15.1%
  8. 11 Mar 2026+10.9%

    Nothing announced by INMB that day or the session before.

  9. 23 Dec 2025-9.6%
  10. 9 Dec 2025+6.4%

Share of unusual movement by asset

For each asset, the share of INMB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Pegipanermin
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—41%
Sessions with no dated event—57%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Soluble TNF (selective)Biologic (subtype unspecified)
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3——$16M$4.7M-$3.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$18M$1.3M-$3.2M operating cash flowreport ↗
2026-Q1—$3.6M$21M$5.4M-$3.4M operating cash flowreport ↗
2025-Q3—$4.9M$28M$6.5M-$5.4M operating cash flowreport ↗
2025-Q2—$5.8M$33M$24M-$7.4M operating cash flowreport ↗
2025-Q1$0.1M$7.6M$19M$9.7M-$6.8M operating cash flowreport ↗
2024-Q3—$10M$34M$12M-$7.0M operating cash flowreport ↗
2024-Q2—$7.0M$31M$9.8M-$7.9M operating cash flowreport ↗
2024-Q1<$0.1M$8.7M$26M$11M-$7.5M operating cash flowreport ↗
2023-Q3<$0.1M$6.0M$42M$8.6M-$4.3M operating cash flowreport ↗
2023-Q2$0.1M$4.2M$48M$6.5M-$3.2M operating cash flowreport ↗
2023-Q1<$0.1M$4.1M$51M$6.5M-$1.1M operating cash flowreport ↗
2022-Q3$0.1M$5.2M$57M$7.7M-$3.4M operating cash flowreport ↗
2022-Q2<$0.1M$4.2M$61M$6.8M-$4.8M operating cash flowreport ↗
2022-Q1$0.2M$4.3M$67M$6.9M-$8.9M operating cash flowreport ↗
2021-Q3<$0.1M$6.5M—$9.5M-$7.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.1M$21M$25M$11M-$23M operating cash flowreport ↗

For fiscal year 2025, INmune Bio reported revenue of $0.05M, up 400.0% YoY, with R&D spend of $20.66M, down 37.7% YoY. Cash and equivalents stood at $24.75M, and the company reported a net loss of $45.93M, with reported quarterly net burn of $45.93M.

The company did not provide financial guidance but disclosed regulatory and clinical milestones. CORDStrom regulatory submissions are planned for a UK MAA in July 2026, EU MAA in September 2026, and FDA BLA in December 2026. XPro’s Phase II trial missed its primary and key secondary endpoints, though a prespecified enriched subgroup showed favorable signals, and an end-of-Phase 2 FDA meeting in January 2026 confirmed alignment on a proposed integrated Phase 2b/3 strategy, which the company intends to pursue through a strategic partnership rather than independently. INKmune’s Phase I/II trial in metastatic castrate-resistant prostate cancer completed enrollment in Q4 2025, with top-line data expected about six months later, but the company does not intend to advance INKmune further at this time due to capital constraints.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY<$0.1M$33M$21M$11M-$33M operating cash flowreport ↗
2023-FY$0.2M$20M$36M$7.5M-$12M operating cash flowreport ↗
2022-FY$0.4M$17M$52M$6.8M-$23M operating cash flowreport ↗
2021-FY$0.2M$21M$75M$7.6M-$29M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-15Clark Ronnie Duane · directorAward / grant (derivative)100,000——Form 4
2026-09-15SAPIRSTEIN JAMES · directorAward / grant (derivative)100,000——Form 4
2026-07-02Moss David J · director, Chief Executive OfficerOption exercise9,014$1.40$13KForm 4
2026-07-02Lowdell Mark William · Chief Scientific OfficerOption exercise7,211$1.40$10KForm 4
2026-07-02Juda Scott · directorOption exercise14,801$1.40$21KForm 4
2026-07-02Moss David J · director, Chief Executive OfficerOption exercise (derivative)9,014$0.13$1KForm 4
2026-07-02Lowdell Mark William · Chief Scientific OfficerOption exercise (derivative)7,211$0.13$901Form 4
2026-07-02Juda Scott · directorOption exercise (derivative)14,801$0.13$2KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 81 reporting institutions held 5.4M shares ($6.1M, 17.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.1,194,112$1.3M
2VANGUARD CAPITAL MANAGEMENT LLC687,015$776K
3GEODE CAPITAL MANAGEMENT, LLC494,969$559K
4STATE STREET CORP290,879$329K
5AQR CAPITAL MANAGEMENT LLC270,317$305K
6UBS Group AG253,340$286K
7GOLDMAN SACHS GROUP INC231,586$262K
8RAYMOND JAMES FINANCIAL INC203,245$230K
9SUSQUEHANNA INTERNATIONAL GROUP, LLP194,391$220K
10NORTHERN TRUST CORP184,225$208K
11Dauntless Investment Group, LLC183,476$207K
12VANGUARD PORTFOLIO MANAGEMENT LLC129,218$146K
13VANGUARD FIDUCIARY TRUST CO123,184$139K
14Westside Investment Management, Inc.108,300$122K
15Bank of New York Mellon Corp53,628$61K